Our findings highlight the significance of a YAP–IGF-1R signaling loop in HCC sorafenib resistance and provide novel potential targets for future therapeutics to treat patients with sorafenib-resistant HCC (Figure 6). Here, IGF1R is linked to hepatocellular carcinoma.